Vaccine for falciparum malaria

Patent metadata

Field	Value
Publication number	US-10272145-B2
Application number	US-201615298021-A
Country	US
Kind code	B2
Filing date	Oct 19, 2016
Priority date	Dec 2, 2011
Publication date	Apr 30, 2019
Grant date	Apr 30, 2019

Abstract

The invention provides compositions and methods for preventing or reducing the severity of malaria.

First claim

The invention claimed is:

1. A vaccine for reducing the severity of malaria or immunizing against malaria comprising a composition that leads to inhibition of parasite egress from red blood cells or inhibits parasite egress from said red blood cells, wherein said composition comprises a purified polypeptide comprising the amino acid sequence of PfSEP1 (SEQ ID NO:3) or a fragment thereof, said fragment thereof comprising the amino acid sequence of PfSEP1A (SEQ ID NO:2), further comprising an adjuvant.

2. The vaccine of claim 1 , wherein said composition comprises a purified polypeptide comprising the amino acid sequence of SEQ ID NO: 2.

3. The vaccine of claim 1 , wherein said composition further comprises a purified polypeptide comprising the amino acid sequence of CDPK5 (SEQ ID NO:47), SERA5 (SEQ ID NO:70, 72), PfSUB1 (SEQ ID NO:74), or PfPKG (SEQ ID NO:76).

4. The vaccine of claim 1 , wherein said composition comprises a purified polypeptide that elicits an anti-PfSEP-1 antibody response.

5. The vaccine of claim 1 , wherein said composition comprises a purified anti-PfSEP-1 antibody or antigen binding fragment thereof.

6. The vaccine of claim 1 , wherein said composition further comprises a purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 10, 14, 18, 22, 30, 34, 38, 42, 46, 66 and 72.

7. The vaccine of claim 1 , wherein said composition further comprises a purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 8, 11, 15, 19, 22, 31, 35, 39, 43, 47, 67, 70, 74, and 76 or fragments thereof.

8. The vaccine of claim 1 , wherein said composition further comprises a purified polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 6, 7, 10, 11, 14, 15, 18, 19, 22, 23, 30, 31, 34, 35, 28, 39, 42, 43, 46, 47, 66, 67, 70, 72, 74, and 76 or an immunogenic fragment thereof.

9. The vaccine of claim 1 , wherein said composition further comprises a purified polypeptide comprising an amino acid sequence of 6, 7, 10, 11, 14, 15, 18, 19, 22, 23, 30, 31, 34, 35, 28, 39, 42, 43, 46, 47, 66, 67, 70, 72, 74, and/or 76.

10. An isolated peptide comprising a peptide having at least 95% to 99% identity with the sequence of SEQ ID NO: 3, wherein said peptide elicits an anti-PfSEP1 antibody response against P. falciparum malaria, further comprising an adjuvant.

11. The peptide of claim 10 , wherein said peptide comprises SEQ ID NO: 3 or a fragment thereof, wherein said fragment comprises the amino acid sequence of SEQ ID NO: 2.

12. An isolated peptide comprising the sequence of SEQ ID NO: 3, wherein said peptide elicits an anti-PfSEP1 antibody response against P. falciparum malaria, further comprising an adjuvant.

Assignees

• Rhode Island Hospital
• Seattle Biomedical Res Institute

Inventors

• Kurtis Jonathan
• Nixon Christian Parcher
• Raj Dipak Kumar
• Friedman Jennifer Frances
• Fried Michal
• Duffy Patrick Emmet

Classifications

• A61K39/015 Primary

  Hemosporidia antigens, e.g. Plasmodium antigens · CPC title

• A61K2039/575

  humoral response · CPC title

• A61K39/39575

  against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants · CPC title

• C07K2317/34

  Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title

• A61K2039/54

  characterised by the route of administration · CPC title